Home
Technologies Available for Licensing

Technologies Available for Licensing

For Licensing Opportunities, please contact the ORTA at USArmy.Detrick.MEDCOM-USAMRMC.List.ORTA@health.mil


NEUTRALIZING ANTIBODIES TO EBOLA VIRUS GLYCOPROTEIN AND THEIR USE

Neutralizing antibodies and antigen binding fragments that specifically bind to Ebola virus glycoprotein are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting Ebola virus using the antibodies and antigen binding fragments are disclosed. The antibodies, antigen binding fragments, nucleic acids, and vectors, can be used, for example, to prevent and/or treat Ebola virus infection in a subject.


Docket:RIID 16-13-EP01

Publication/Issued No.:3218397

Publication/Issue Date:2021-02-24

Categories: Antibody Technologies

Lab:RIID

Inventor(s):SULLIVAN, N.; TREFRY, J.

For Licensing Opportunities, please contact the ORTA at USArmy.Detrick.MEDCOM-USAMRMC.List.ORTA@health.mil
 
 

Last Modified Date: 16 May 2023

This Web site provides an introduction to the Office of Research and Technology Applications (ORTA) and contains official Government information.

Its use is intended for members of the general public, news media and Military Health System beneficiaries.

Please address questions or concerns about this Web site to the USAMRDC Public Affairs Office at:
USArmy.Detrick.MEDCOM-USAMRMC.List.ORTA@health.mil or by telephone at (301)619-2736.